A phase I study of CLAG regimen [cladribine, cytarabine] in combination with imatinib mesylate (Gleevec) in refractory or relapsed leukemia.

Trial Profile

A phase I study of CLAG regimen [cladribine, cytarabine] in combination with imatinib mesylate (Gleevec) in refractory or relapsed leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2013

At a glance

  • Drugs Imatinib (Primary) ; Cladribine; Cytarabine
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jan 2009 Planned patient numbers amended from 12 to 18 as reported by ClinicalTrials.gov.
    • 01 Oct 2006 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top